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A B S T R A C T
Although metabolic syndrome was not extensively studied in type 1 diabetes, higher insulin resistance, the core fea-
ture of the syndrome was found to be associated with increased risk of developing microvascular complications. As dia-
betic nephropathy may progress to advanced lesion before microalbuminuria appears, we investigated the association of
the metabolic syndrome and estimated glucose disposal rate (eGDR) with urinary albumin excretion (UAE), retinopathy
and neuropathy in normoalbuminuric type 1 diabetic patients. Two hundred and 98 patients (UAE <30 mg / 24 h at
three occasions) were divided according to the IDF metabolic syndrome; eGDR (mg kg–1 min–1) was calculated: 24.31–
(12.22 ´ WHR) – (3.29 ´ HT) – (0.57 ´ HbA1c), (WHR=waist-to-hip ratio, HT=hypertension). Patients with (n=99)
compared to those without metabolic syndrome (N=199) showed higher UAE (15.96±9.10; 13.48±8.36 mg / 24 h), C-re-
active protein (2.39±4.09;1.12±2.03 mg/L), prevalence of retinopathy (70.7;55.27%) and polyneuropathy (80.8; 68.3%),
and lower eGDR (5.75±1.74; 8.96±1.9), (p>0.05). In patients with high-normal UAE, retinopathy and polyneuropathy
eGDR was significantly lower compared with patients with low-normal UAE, and without retinopathy and polyneuro-
pathy. In multiple regression analysis UAE and retinopathy were associated with diabetes duration (b= –0.20, b= –0.62),
eGDR (b= – 0.106; b= –0.041), metabolic syndrome (b=0.49, b=0.28), (p>0.05). In type 1 diabetic patients insulin resis-
tance and IDF defined metabolic syndrome are associated with high-normal UAE, retinopathy and polyneuropathy. The
predictive value of the metabolic syndrome for development of microalbuminuria and retinopathy needs to be assessed in
further follow-up studies.
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Introduction
In spite of medical controversies surrounding its
pathogenesis and clinical presentation, the metabolic
syndrome has been widely accepted as an important risk
factor for the development of type 2 diabetes and cardio-
vascular disease1,2. It is characterized by central obesity,
dyslipidemia, impaired glucose metabolism and hyper-
tension with insulin resistance representing a key part of
the syndrome3. During the last decades other distur-
bances such as NASH, PCO, microalbuminuria, abnor-
malities in fibrinolysis and coagulation have been linked
to the syndrome1. Although a number of these compo-
nents can be found in type 1 diabetic patients, the preva-
lence and significance of the metabolic syndrome in type
1 diabetes has been less extensively studied4,5.
Few studies have investigated the impact of the meta-
bolic syndrome on the development of microvascular
complications in type 1 diabetes6–8.
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A recent introduction of a validated method for esti-
mated glucose disposal rate (eGDR) has allowed easier
assessment of insulin resistance by calculating a score
based on clinical factors of the patient9.
Higher insulin resistance calculated by eGDR was
found to be associated with increased risk of developing
both micro and macrovascular complications in type 1 di-
abetic patients8. Insulin resistance has been suggested to
be implicated in the development of diabetic nephropa-
thy.
Increased insulin resistance has been documented in
type 1 diabetic patients with microalbuminuria and the
metabolic syndrome has been more frequent in patients
with advanced diabetic nephropathy. Insulin sensitivity
has been shown to be more strongly associated with AER
than creatinine clearance, confirming that the change in
insulin sensitivity preceded the decline in creatinine
clearance10.
Emerging data indicate that the complex interrela-
tions between insulin resistance and low-grade inflam-
matory markers contribute to the development of micro-
albuminuria as a manifestation of endothelial dysfunc-
tion7,11,12.
On the other hand, the degree of albuminuria, as a
hallmark of diabetic renal disease, is closely related to
the progression of diabetic nephropathy. In type 1 dia-
betic patients high normal urinary albumin excretion
UAE represents a significant predictive factor of progres-
sion to microalbuminuria13,14.
In view of the fact that glomerular and arteriolar ab-
normalities have already been developed in microalbu-
minuric subjects, it would be of special clinical interest to
investigate insulin resistance, inflammatory markers
and the presence of the metabolic syndrome at the nor-
moalbuminuric stage11,15.
The present study was undertaken to characterise a
large group of normoalbuminuric type 1 diabetic patients
according to the presence of the metabolic syndrome and
determine a possible association of the metabolic syn-
drome, eGDR and inflammatory markers with UAE,
retinopathy and neuropathy.
Patients and Methods
Two hundred and 98 patients with type 1 diabetes
(146 men, 152 women) hospitalized at the Inpatient De-
partment of the »Vuk Vrhovac« University Clinic in the
period between January 2008 and September 2010, were
included in the study.
Type 1 diabetes was diagnosed according to the pres-
ence of either ICA or GAD antibodies. ICA (islet cell anti-
bodies) were determined using indirect immuofluores-
cence technique (IIF) on human pancreatic frozen tissue
(0 negative blood group). The determination was done in
human serum of patients and visualization using fluores-
cence microscope.
GAD (glutamic acid decarboxylase) antibodies deter-
mination was performed using commercial ELISA kit
(Euroimmun, Lubeck, Deutschland). Our laboratory
that was performing the test has successfully partici-
pated in DASP – Diabetes Antibody Standardization Pro-
gram, 201016.
The following inclusion criteria were used: diabetes
duration >1 year, patient age >18 years, UAE <30
mg/24h measured on three occasions, and absence of
acute or chronic inflammatory and renal disease. All pa-
tients were treated by intensive insulin therapy, and 94
among them were taking ACE inhibitors.
Patients were diagnosed with the metabolic syndrome
according to the IDF definition when their waist circum-
ference was ³94 in men and ³80 in women, and at least
one of the following three criteria was met: 1) triglycer-
ides ³1.7 mmol/L or specific hypolipemic treatment; 2)
HDL <1.03 mmol/L in men and <1.29 mmol/L in wo-
men, or specific hypolipemic treatment and 3) systolic
blood pressure ³130 mmHg or diastolic blood pressure
³85 mmHg, or specific antihypertensive treatment. All
patients were considered to fulfil the criterion of high
blood glucose as defined by the IDF.
Estimated glucose disposal rate – eGDR was calcu-
lated using the equation: eGDR = 24.31 – (12.22 ´ WHR)
– (3.29 ´ HT) – (0.57 ´ HbA1c). The units were mg kg–1
min–1, WHR=waist-to-hip ratio, HT=hypertension.
This equation was derived from a substudy of 24 par-
ticipants in the EDC Study who underwent euglycemic-
-hyperinsulinemic clamp studies9. Direct ophtalmoscopy
was performed with dilated pupils by an experienced
ophthalmologist especially trained in screening for and
treatment of diabetic retinopathy. Retinopathy was clas-
sified according to the European Protocol17.
Urinary albumin concentration and C-reactive pro-
tein were determined by an immunoturbidimetric assay
(Olympus diagnostics, Lismeehan, Ireland)., as was gly-
cosylated haemoglobin (HbA1c) (Bayer, Terrytown,
USA).
Homocysteine was measured by chemiluminiscence
on an ACS+189 analyzer (Bayer diagnostic, Tarrytown,
USA).
The results are expressed as X±SD. Statistical analy-
sis was performed by Student's t test (differences be-
tween the two groups), Pearson test (correlation) and
multiple regression analysis (stepwise linear regression,
beta indicating the regression coefficient), with p<0.05
considered to be statistically significant. The study pro-
tocol was reviewed and approved by the Clinic’s Ethics
Committee. All participants signed an informed consent
on entry to the study.
Results
Clinical data of normoalbuminuric type 1 diabetic pa-
tients divided according to the presence of the metabolic
syndrome are given in table 1. The prevalence of the met-
abolic syndrome as defined according to IDF criteria was
32.88%, amounting to 34.24% in men and 30.92% in
women. Patients with the metabolic syndrome were ol-
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der, had a longer duration of the disease and showed
lower eGDR, higher UAE, CRP and homocysteine value
(Table 1). Prevalence of retinopathy in patients with the
metabolic syndrome was significantly higher compared
to those without the syndrome, while the prevalence of
neuropathy did not reach the statistical significance (Fig-
ure 1).
Among patients with the metabolic syndrome, the
most frequent combination of diagnostic criteria was
waist circumference (as required by definition) hyperten-
sion and triglycerides, which was shown in 26.26% of pa-
tients. Waist circumference, hypertension and low HDL
were seen in 21.21% of patients (Figure 2). In the study
population a significant correlation between UAE and
eGDR was found (Figure 3). In multiple regression anal-
ysis with age, duration of diabetes, eGDR, LDL level,
CRP and homocysteine as independent variables, the
presence of the metabolic syndrome was associated with
age, duration of the disease, eGDR, CRP and LDL choles-
terol.
In multiple regression analysis with age, duration of
the disease, IDF metabolic syndrome, eGDR, LDL, CRP,
L. Duvnjak et al.: The Metabolic Syndrome in Type 1 Diabetes, Coll. Antropol. 36 (2012) 4: 1373–1378
1375
TABLE 1
CLINICAL CHARACTERISTICS OF NORMOALBUMINURIC TYPE 1 DIABETIC PATIENTS DIVIDED ACCORDING TO THE PRESENCE
OF THE METABOLIC SYNDROME
Metabolic syndrome absent
(N=199)
Metabolic syndrome present
(N=99)
p
Age (years) 41±11.63 46±11.95 0.004
Gender M/F
96/146 (65.8%) – male
105/152 (69.1%) – female
50/146 (34.2%) – male
47/152 (30.9%) – female
NS
Duration of the disease (years) 17±10.23 20±9.68 0.05
BMI (kg/m2) 23.32±2.62 27.26±3.56 0.0001
Waist (cm)
Men
Women
79.04±8.12
85.33±8.22
82.1±6.2
92. 89±10.49
97.17±8.56
87.77±10.19
0.0001
UAE (mg / 24h) 13.48±8.36 15.96±9.10 0.02
A1C (%) 7.71±1.5 7.8±1.43 NS
eGDR (mg kg–1 min–1) 8.96±1.9 5.75±1.74 0.0001
LDL cholesterol (mmol/L) 2.9±0.7 3.36±0.95 0.0001
HDL cholesterol (mmol/L) 1.61±0.45 1.47±0.47 0.02
Triglycerides (mmol/L) 1.0±0.52 1.55±1.14 0.0001
C-reactive protein 1.12±2.03 2.39±4.09 0.0001
Homocysteine 9.01±2.92 10.36±6.91 0.03
Systolic blood pressure (mmHg) 125.29±14.73 135.47±17.54 0.0001
Diastolic blood pressure (mmHg) 79.53±8.01 85.98±7.21 0.0001
Retinopathy 110/199 (55.3%) 70/99 (70.7%) 0.04
Polineuropathy 136/199 (68.3%) 80/99 (80.8%) NS
Data are expressed as X±SD, except for gender, retinopathy and polineuropathy
Fig. 1. Prevalence of retinopathy and polineuropathy in type 1 di-
abetic patients with and without metabolic syndrome.
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Fig. 2. Distribution of IDF criteria of the metabolic syndrome in
99 normoalbuminuric type 1 diabetic patients.
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homocysteine, systolic and diastolic blood pressure and
HbA1c as independent variables, UAE was associated
with the duration of diabetes, eGDR, IDF metabolic syn-
drome and HbA1c.
In multiple regression analysis with age, duration of
the disease, IDF metabolic syndrome, eGDR, LDL, CRP,
homocysteine, systolic and diastolic blood pressure, UAE
and HbA1c as independent variables, retinopathy was
associated with the duration of diabetes, eGDR, IDFmet-
abolic syndrome and HbA1c. In multiple regression anal-
ysis with age, duration of the disease, IDF defined meta-
bolic syndrome, eGDR, LDL, CRP, homocysteine,systolic
and diastolic blood pressure, UAE and HbA1c as inde-
pendent variables, polineuropathy was associated with
age, duration of diabetes, eGDR, IDF metabolic syn-
drome, LDL and HbA1c (Table 2).
Discussion
The results of the present study show that the meta-
bolic syndrome is a frequent finding in type 1 diabetic pa-
tients. Although similar prevalence has previously been
reported, this is the first study documenting the presence
of the metabolic syndrome in a large number of strictly
normoalbuminuric subjects with type 1 diabetes7.
Patients with the metabolic syndrome were more
likely to show increased insulin resistance, evidence of
low-grade inflammation and high normal UAE compared
to those without the syndrome.
The relationship between insulin resistance, inflam-
mation and endothelial dysfunction in diabetes is com-
plex18–23.
As originally proposed by Steno investigators, micro-
albuminuria is a marker of vascular damage and is asso-
ciated with the development of renal complications in di-
abetic patients18. Increased insulin resistance and
inflammatory activity in type 1 diabetic patients with
microalbuminuria have been previously demonstra-
ted11,12,18–23.
An analysis of the cross-sectional FinnDiane study
showed lower eGDR and increased prevalence of the met-
abolic syndrome (defined according to NCEP criteria) in
type 1 diabetic patients with microalbuminuria7.
Increased CRP concentrations have been documented
in type 1 diabetic patients with macro-and microalbumi-
nuria11,20.
The structural injury in diabetic nephropathy devel-
ops in silence over years and may have progressed to ad-
vanced lesion before a clinically detectable abnormality
like microalbuminuria appears23. Thus, the temporal
link between endothelial dysfunction, linked to insulin
resistance and low-grade inflammation, and the appear-
ance of microalbuminuria should be considered. Strat-
egies to prevent diabetic nephropathy should focus on
early factors that could influence the development of
microalbuminuria.
According to the results of longitudinal studies high
normal UAE, besides high blood pressure and poor gly-
caemic control, has been established as a significant pre-
dictive factor of progression to microalbuminuria13,14.
The results of our study suggest a possible role of insulin
resistance and CRP, the acute phase reactant and a very
sensitive marker of acute inflammatory reaction in pre-
dicting the progression of high-normoalbuminuric stage
to microalbuminuria.
It has been previously suggested that endothelial dys-
function might precede microalbuminuria by two or three
years25.
L. Duvnjak et al.: The Metabolic Syndrome in Type 1 Diabetes, Coll. Antropol. 36 (2012) 4: 1373–1378
1376
Fig. 3. Correlation between UAE and eGDR in normoalbuminu-
ric Type 1 diabetic patients.
TABLE 2
RESULTS OF MULTIPLE REGRESSION ANALYSIS IN NORMOALBUMINURIC TYPE 1 DIABETIC PATIENTS
Independent variables
Dependent
variables
Age Duration of
diabetes
eGDR CRP LDL HbA1c
Metabolic
syndrome
UAE
b= –0.20
(p=0.0001)
b= –0.106
(p=0.01)
b=0.107
(p=0.001)
b=0.49
(p=0.0001)
Retinopathy
b= –0.62
(p=0.0001
b= –0.041
(p=0.002)
b=0.049
(p=0.02)
b=0.28
(p=0.0001)
Polineuropathy
b= –0.24
(p=0.0001)
b= –0.34
(p=0.0001)
b= –0.049
(p=0.0001)
b=0.088
(p=0.025)
b=0.055
(p=0.004)
b=0.218
(p=0.0001)
* b – regression coefficient
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A small study on 16 patients has demonstrated in-
creased insulin resistance before the development of
microalbuminuria26.
We gave evidence in a large number of normoalbumi-
nuric type 1 diabetic patients of the presence of increased
insulin resistance already at the normoalbuminuric sta-
ge. Our data demonstrate a close link between chronic
glucose exposure, insulin resistance and inflammation.
The results of multiple regression analysis showed an
independent relation of diabetes duration, CRP and
eGDR with the presence of the metabolic syndrome, sug-
gesting that chronic exposure to glucose may stimulate
the increase in insulin resistance and induce inflamma-
tory activity. Insulin resistance, as a core of the metabolic
syndrome, generates visceral adiposity, dyslipidemia and
hypertension, the well known clinical manifestations of
the condition3,4. Insulin resistance, inflammation and en-
dothelial dysfunction are interrelated. As they progress
with time, it is not possible to determine which factor
precedes the others28–30.
However, our results suggest that insulin resistance
and low grade inflammation might induce endothelial
dysfunction, manifested by the elevation of UAE within
the normoalbuminuric range.
As the metabolic syndrome, eGDR and CRP represent
potentially modifiable risk factors, their detection in pa-
tients with high-normal UAE can be of clinical signifi-
cance. The results of the presents study suggest that
strategies to decrease insulin resistance and inflamma-
tory activity, and improve endothelial function should be
introduced early in the course of the disease. Introducing
appropriate therapy at this stage, beside the one aimed
at treating conventional risk factors, could stop or delay
the progression to microalbuminuria.
We have also noticed that normoalbuminuric type 1
diabetic subjects with the metabolic syndrome showed
increased prevalence of retinopathy and neuropathy in
comparison to those without the syndrome. These find-
ings are consistent with those from the Metascreen, a
multicenter diabetes clinic-based survey. This cross-sec-
tional study found the metabolic syndrome, defined ac-
cording to IDF or AHA/NHLBI criteria, to be an inde-
pendent indicator of the presence of nephropathy and
neuropathy in type 1 diabetes6. A strong association be-
tween the waist-to-hip ratio and triglyceride level, both
components of the metabolic syndrome, and retinopathy
has also been previously reported30. In this study, insulin
resistance has been suggested as a unifying feature of
these factors to account for their relationship with reti-
nopathy28.
A direct impact of insulin resistance on the pathoge-
nesis of microangiopathy has been suggested27–29. Path-
way-selective insulin resistance in the phosphatidylino-
sitol-3-kinase signaling pathway with uneffected extra-
cellular signal-regulated kinase-dependent pathway tips
the balance of insulin action in favour of abnormal vaso-
reactivity and angiogenesis leading to microangiopa-
thy27.
Kilpatrick also found lower eGDR to be associated
with increased risk of both micro- and macrovascular
complications8.
In contrast to other studies, this analysis of the DCCT
found the IDF definition of the metabolic syndrome to be
of little clinical utility in distinguishing type 1 diabetic
patients prone to developing micro- or macrovascular
complications8. Poor predictive outcome was attributed
to the fact that the metabolic syndrome was primarily in-
tended for type 2 diabetic patients. The lack of specificy
of the IDF definition in identifying type 1 diabetic pa-
tients at an increased risk of developing complications
was linked to the lower waist circumference tresholds
used.
However, our results have shown that beside eGDR,
metabolic syndrome itself might be an indicator of micro-
vascular complications.
The metabolic syndrome may represent a simple tool
to stratify type 1 diabetic patients according to the ex-
pected development of microalbuminuria and retinopa-
thy. Considering the high morbidity rate of diabetic
microvascular complications, the focus of therapeutic in-
terventions needs to shift from the treatment of late-
-stage disease to the prevention31–32.
Although it is obvious that the complex pathogenesis
of diabetic microvascular complications will remain un-
clarified in clinical trials, our data may help clinicians in
approaching type 1 diabetic patients with the metabolic
syndrome.
The presence of the metabolic syndrome at the nor-
moalbuminuric stage might point to patients at an in-
creased risk of developing microalbuminuria and retino-
pathy, which needs to be clarified in future follow-up
studies of normoalbuminuric patients.
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METABOLI^KI SINDROM JE POVEZAN S VISOKO NORMALNIM IZLU^IVANJEM ALBUMINA
U MOKRA]I TE RETINOPATIJOM U NORMOALBUMINURI^NIH BOLESNIKA SA [E]ERNOM
BOLE[]U TIPA 1
S A @ E T A K
Iako metaboli~ki sindrom nije {iroko prou~avan u {e}ernoj bolesti tipa 1, utvr|ena je povezanost pove}ane inzu-
linske rezistencije, glavne odrednice sindroma, s povi{enim rizikom razvijanja mikrovaskularnih komplikacija. Kako se
dijabeti~ka nefropatija mo`e razviti do uznapredovalog o{te}enja prije nego se pojavi mikroalbuminurija, istra`ili smo
povezanost metaboli~kog sindroma i procijenjene stope razdiobe glukoze (eGDR) s urinarnim izlu~ivanjem albumina
(UAE), retinopatijom i neuropatijom u normalbuminuri~nih bolesnika sa {e}ernom bole{}u tipa 1. 298 bolesnika (UAE
<30 mg / 24 h u tri mjerenja) podijeljeni su prema IDF (International Diabetes Federation) kriteriju na one s i one bez
metaboli~kog sindroma; eGDR (mg kg–1 min–1) je izra~unata: 24,31 – (12,22 ´ WHR) – (3,29 ´ HT) – (0,57 ´ HbA1c),
(WHR=waist-to-hip ratio – omjer struk:bok, HT=hipertenzija). Bolesnici s (N=99) u usporedbi s onima bez meta-
boli~kog sindroma (n=199) pokazali su povi{ene UAE (15,96±9.10; 13,48±8.36 mg / 24 h), C-reaktivni protein
(2,39±4,09; 1,12±2,03 mg/L), prevalenciju retinopatije (70,7; 55,27%) i polineuropatiju (80,8; 68,3%), a ni`u eGDR
(5,75±1,74; 8,96±1,9), (p>0,05). Kod bolesnika s visoko-normalnim UAE, retinopatijjom i polineuropatijom, eGDR je
bila zna~ajno ni`a u usporedbi s bolesnicima s nisko-normalnom UAE te bez retinopatije i polineuropatije. UAE i reti-
nopatija su u multiploj regresijskoj analizi bili povezani s trajanjem dijabetesa (b= –0,20, b= –0,62), eGDR (b= –0,106;
b= –0,041), metaboli~kim sindromom (b=0,49, b=0,28), (p>0,05). U bolesnika sa {e}ernom bole{}u tipa 1 inzulinska
rezistencija i metaboli~ki sindrom definiran po IDF-u bili su povezani s visoko-normalnom UAE, retinopatijom i poli-
neuropatijom. Prediktivnu vrijednost metaboli~kog sindroma za razvoj mikroalbuminurije i retinopatije treba procije-
niti daljnjim istra`ivanjima.
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